Short interest for Appili Therapeutics gives investors a sense of the degree to which investors are betting on the decline of Appili Therapeutics's stock. Short interest data is updated every two weeks.

Appili Therapeutics Stock (OTC:APLIF), Short Interest Report

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir.

Penny Stocks

APLIF

TSX:APLI


  By David Bautz, PhD

OTC:APLIF | TSX:APLI.TO

READ THE FULL APLIF RESEARCH REPORT

APLIF: Advancing Multiple Programs to Combat Infectious Diseases…

Bautz: By David Bautz, PhD

OTC:APLIF | TSX:APLI.TO

READ THE FULL APLIF RESEARCH REPORT

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

APLIF: U.S. DoD to Provide Over US$10 Million in Funding for ATI-1701…

APPILI THERAPEUTICS INC by Appili Therapeutics Inc.

Appili Therapeutics Inc

Ingersoll Rand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>) reported quarterly Adj earnings of $0.78 per share which beat the analyst consensus estimate of $0.69 by 13.04 percent. This is a 20 percent increase over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $1.670 billion which missed the analyst consensus estimate of $1.700 billion by 1.74 percent. This is a 2.50 percent increase over sales of $1.629 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Ingersoll Rand Q1 2024 Adj EPS $0.78 Beats $0.69 Estimate, Sales $1.670B Miss $1.700B Estimate

El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 57.14 percent. This is a 57.14 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $116.153 million which beat the analyst consensus estimate of $111.083 million by 4.56 percent. This is a 1.42 percent increase over sales of $114.526 million the same period last year.

LOCO

El Pollo Loco Holdings Q1 2024 Adj EPS $0.22 Beats $0.14 Estimate, Sales $116.153M Beat $111.083M Estimate

Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) reported quarterly earnings of $2.09 per share which beat the analyst consensus estimate of $1.99 by 5.03 percent. The company reported quarterly sales of $469.759 million which missed the analyst consensus estimate of $494.520 million by 5.01 percent. This is a 6.08 percent decrease over sales of $500.148 million the same period last year.

Quaker Houghton Q1 2024 Adj EPS $2.09 Beats $1.99 Estimate, Sales $469.759M Miss $494.520M Estimate

MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 15.15 percent. This is a 16.67 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $49.067 million which beat the analyst consensus estimate of $48.733 million by 0.68 percent. This is a 13.93 percent decrease over sales of $57.005 million the same period last year.

MagnaChip Semiconductor Q1 2024 Adj EPS $(0.28) Beats $(0.33) Estimate, Sales $49.067M Beat $48.733M Estimate

AAPL

Apple Q2 2024 Services Sales $23.86B

Dividends

Buybacks

Apple Board Authorized Additional $110B For Share Repurchase, Increases Dividend 4% To $0.25

<h3>Gainers</h3>
<ul>
<li>El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) shares increased by 14.1% to $9.81 during Thursday's after-market session. The company's market cap stands at $305.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock moved upwards by 7.03% to $0.35. The company's market cap stands at $18.1 million. </li>
<li>Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) shares moved upwards by 6.53% to $3700.0. The company's market cap stands at $125.8 billion. The company's, Q1 earnings came out today. </li>
<li>RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) shares increased by 5.0% to $5.25. The market value of their outstanding shares is at $185.0 million. </li>
<li>J-Long Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) shares rose 4.99% to $0.81. The market value of their outstanding shares is at $25.3 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares increased by 4.97% to $0.41. The company's market cap stands at $47.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) shares fell 8.5% to $124.55 during Thursday's after-market session. The market value of their outstanding shares is at $16.4 billion. As per the press release, Q1 earnings came out today. </li>
<li>Fox Factory Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) stock declined by 7.41% to $36.5. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q1 earnings came out today. </li>
<li>Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares declined by 4.89% to $29.01. The market value of their outstanding shares is at $23.3 billion. </li>
<li>Charles &amp; Colvard (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTHR#NASDAQ">CTHR</a>) stock decreased by 4.8% to $0.33. The company's market cap stands at $10.0 million. The company's, Q3 earnings came out today. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) stock declined by 4.26% to $1.8. The company's market cap stands at $104.5 million. </li>
<li>Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) stock declined by 3.72% to $0.87. The market value of their outstanding shares is at $45.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BKNG

CTHR

EXPE

FOSL

FOXF

GDHG

JZXN

MBLY

RMBL

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

Apple Q2 2024 Wearable Sales $7.91B

<h3>Gainers</h3>
<ul>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out today. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares increased by 13.91% to $0.33. The company's market cap stands at $95.9 million. </li>
<li>Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) stock moved upwards by 12.25% to $41.04. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out today. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock moved upwards by 11.29% to $2.26. The company's market cap stands at $19.2 million. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares rose 11.02% to $7.54. The company's market cap stands at $1.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares rose 8.33% to $1.43. The market value of their outstanding shares is at $32.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 7.5% to $1.74 during Thursday's after-market session. The company's market cap stands at $84.6 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 6.7% to $4.18. The market value of their outstanding shares is at $186.8 million. The company's, Q1 earnings came out today. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) shares declined by 6.31% to $5.2. The market value of their outstanding shares is at $186.0 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock declined by 6.12% to $1.06. The company's market cap stands at $3.8 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares fell 5.7% to $1.16. The company's market cap stands at $2.2 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares decreased by 5.67% to $15.5. The market value of their outstanding shares is at $629.5 million. The company's, Q2 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

APVO

ARDX

CRDF

INDP

JAGX

NKGN

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

TNDM

TWST

VREX

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) stock increased by 12.3% to $168.0 during Thursday's after-market session. The company's market cap stands at $9.4 billion. The company's, Q3 earnings came out today. </li>
<li>iSun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) shares moved upwards by 5.03% to $0.15. </li>
<li>Richtech Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) stock rose 4.47% to $1.4. The company's market cap stands at $92.7 million. </li>
<li>Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) stock moved upwards by 4.01% to $28.21. The market value of their outstanding shares is at $865.5 million. As per the press release, Q2 earnings came out today. </li>
<li>Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) stock rose 3.86% to $0.24. The market value of their outstanding shares is at $70.7 million. </li>
<li>Greenwave Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) stock moved upwards by 3.71% to $0.06. The market value of their outstanding shares is at $9.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Terran Orbital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) stock declined by 19.4% to $1.04 during Thursday's after-market session. The company's market cap stands at $209.9 million. </li>
<li>AAON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) shares decreased by 13.59% to $78.54. The market value of their outstanding shares is at $6.4 billion. The company's, Q1 earnings came out today. </li>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) stock decreased by 13.09% to $1.66. The company's market cap stands at $268.1 million. The company's, Q1 earnings came out today. </li>
<li>LSI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) stock decreased by 8.79% to $13.61. The market value of their outstanding shares is at $395.6 million. </li>
<li>Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) shares fell 8.17% to $4.5. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>JanOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAN#NASDAQ">JAN</a>) shares fell 6.88% to $3.66. The market value of their outstanding shares is at $31.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAON

CTOS

GWAV

ISUN

LLAP

LYTS

MATW

PCTY

STEM

12 Industrials Stocks Moving In Thursday's After-Market Session

Apple Q2 2024 iPad Sales $5.56B

<h3>Gainers</h3>
<ul>
<li>OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) stock increased by 20.2% to $13.16 during Thursday's after-market session. The company's market cap stands at $498.0 million. As per the news, the Q1 earnings report came out today. </li>
<li>Digimarc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMRC#NASDAQ">DMRC</a>) shares increased by 12.78% to $25.5. The market value of their outstanding shares is at $545.0 million. The company's, Q1 earnings came out today. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) shares increased by 11.11% to $1.9. The company's market cap stands at $22.6 million. </li>
<li>Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) shares increased by 9.68% to $35.0. The company's market cap stands at $514.7 million. As per the press release, Q2 earnings came out today. </li>
<li>Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) stock rose 7.52% to $61.0. The market value of their outstanding shares is at $4.5 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock increased by 6.46% to $2.47. The company's market cap stands at $24.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sprout Social (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPT#NASDAQ">SPT</a>) shares declined by 22.8% to $37.2 during Thursday's after-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>MariaDB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRDB#NYSE">MRDB</a>) shares declined by 22.44% to $0.41. The company's market cap stands at $27.8 million. </li>
<li>Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) shares decreased by 17.47% to $2.6. The company's market cap stands at $7.8 million. The company's, Q1 earnings came out today. </li>
<li>BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) stock fell 17.35% to $1.43. The company's market cap stands at $346.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) shares declined by 14.02% to $76.5. The company's market cap stands at $25.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares declined by 13.59% to $4.2. The company's market cap stands at $27.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBAI

CLFD

DMRC

FIVN

GREE

MRDB

MRIN

Next Technology Holding Inc. - Ordinary Shares

NXTT

OSPN

WETH

12 Information Technology Stocks Moving In Thursday's After-Market Session

Cryptocurrency trading platform Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) reported first-quarter financial results after the <a href="https://www.benzinga.com/calendars/earnings">market close Thursday.</a>
Here are the key highlights.
What Happened: Coinbase reported total revenue of $1.64 billion, which beat a Street consensus estimate of $1.34 billion, according to data from Benzinga Pro. The company reported GAAP EPS of $4.40. 
The company reported net revenue of $1.6 billion for the quarter, up 72% quarter-over-quarter.
Transaction revenue in the first quarter was $1.08 billion, with consumer transaction revenue totaling $935.2 million. Institutional transaction revenue was $85.4 million in the first quarter.
The company said institutional trading volume and number of active accounts hit all-time highs. 
Net income in the first quarter was $1.2 billion, which included $737 million in pretax crypto asset mark to market gains.
Subscription and services revenue were $511 million in the first quarter, beating previous guidance from the company.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) represented 33% of trading volume and 30% of transaction revenue in the quarter. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) represented 13% of trading volume and 15% of transaction revenue in the quarter.
The company highlighted its Layer 2 platform Base, which saw an 8x increase in developer activity in the first quarter. Base processed more transactions than any Layer 2 over the last 30 days, according to the company.
What's Next: Coinbase is guiding for second-quarter subscription and services revenue to be in a range of $525 million to $600 million.
The company said transaction revenue was $300 million in the month of April.
COIN Price Action: Coinbase shares are down 3.25% to $221.42 in after-hours trading Thursday after gaining 8.93% in the regular trading session. 
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38557434/coinbase-up-300-in-a-year-but-faces-bearish-technicals-ahead-of-q1-earnings">Coinbase Up 300% In A Year, But Faces Bearish Technicals Ahead Of Q1 Earnings</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Coinbase Q2 2024 Earnings Call &#x7C; $COIN" width="500" height="281" src="https://www.youtube.com/embed/WTBvlBtDhmw?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo courtesy of Coinbase.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Markets

Trading Ideas

$BTC

$ETH

COIN

Coinbase Q1 Earnings Highlights: Revenue Beat, Institutional Trading Volume Hits All-Time High, Bitcoin Totals 33% Of Trades

Apple Q2 2024 Mac Sales $7.45B

Guidance

SPXC

SPX Technologies Increases FY24 Adj. EPS From $4.85-$5.15 To $5.15-$5.40 Vs $4.98 Est.; Revenue From $1.93B-$2.00B To $1.965B-$2.025B Vs $1.966B Est.

Apple Q2 2024 iPhone Sales $45.93B

The<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election</a> is less than seven months away, and Predient Joe Biden and former President Donald Trump are <a href="https://www.benzinga.com/general/sports-betting/24/04/38417836/trump-and-biden-get-ready-2024-election-betting-odds-point-to-major-showdown">the presumptive nominees</a>.
According to the latest poll results, a potential rematch between the two candidates has been viewed as a tight race.
What Happened: The newest Morning Consult 2024 election <a href="https://pro.morningconsult.com/trackers/2024-presidential-election-polling">poll </a>of nationally registered voters shows a tie between Biden and Trump. Here are the latest results, with the results <a href="https://www.benzinga.com/general/politics/24/04/38348604/biden-vs-trump-new-poll-shows-tie-in-2024-election-race-one-candidate-gains-among-independent-vo">from the April 21 poll</a> in parentheses.
<ul>
<li>Biden: 42% (42%)</li>
<li>Trump: 42% (42%)</li>
<li>Someone Else: 10% (10%)</li>
<li>Don't Know: 6% (6%)</li>
</ul>
Of Democratic voters polled, 86% chose Biden as their top pick. That&#8217;s one percentage point from the previous poll. Of Republican voters polled, 88% chose Trump as their top pick — in-line with the previous poll.
Independent voters, who could decide the election, selected their 2024 picks as follows, with the April 21 results in parentheses:
<ul>
<li>Biden: 34% (34%)</li>
<li>Trump: 36% (34%)</li>
<li>Someone Else: 18% (21%)</li>
<li>Don't Know: 11% (11%)</li>
</ul>
Related Link: <a href="https://www.benzinga.com/general/politics/24/05/38569790/trump-uses-gag-order-fines-as-fundraising-opportunity-they-want-to-silence-me-they-think-they-ca">Trump Uses Gag Order Fines As Fundraising Opportunity: &#8216;They Want To Silence Me! They Think They Can Bleed Me Dry!&#8217;</a>
Why It's Important: Trump dominated the head-to-head poll against Biden in January and February. But Biden narrowed the gap in March and April and posted a lead over Trump on several occasions.
The new poll shows a high number of voters are still undecided about the election or are considering voting for someone other than the two leading candidates.
After being tied in support with Trump for the Independent vote, Trump now has a two-point lead over the current president. 
Trump also leads in <a href="https://www.benzinga.com/general/politics/24/04/38419834/trump-vs-biden-former-president-dominates-swing-states-but-loses-one-for-first-time-in-new-2024-">six of the seven swing states</a> in a recent Morning Consult poll (Biden carried Michigan). Trump gained support in five of the states and could be adding to his lead in the key battleground states.
Trump's net favorability rating increased to minus two points. The rating is the share of voters who have a favorable view of Trump minus the share with an unfavorable view of the former president. While the figure was negative, it marked the highest rating for Trump since early December.
Morning Consult also reported that the net favorability rating for Trump is up 11 points since a low was reached in January. The climb in the rating comes as Trump is taking part in <a href="https://www.benzinga.com/general/politics/24/04/38326553/trump-hush-money-trial-has-12-jurors-here-are-the-7-men-5-women-to-decide-former-presidents-fate">a criminal trial </a>related to alleged hush money payments.  
Meanwhile, a <a href="https://substack.com/redirect/20b68cf7-fcfc-49ad-a36d-ba406acced56?j=eyJ1IjoiM2t6ZjEifQ.im3RGYRl6IUfFhxylzmPCz7-kHEhOft3hV5Hj-aSLaA" target="_blank" rel="noreferrer noopener">recent Marist poll</a> that breaks out likely voters from registered voters shows Biden leading Trump 50 to 48 (+2) with registered voters, and 52 to 47 (+5) with "definite" or likely voters.
Read Next: <a href="https://www.benzinga.com/general/entertainment/24/05/38591946/joe-bidens-interview-with-howard-stern-shows-his-intimate-side-to-voters-how-hillary-clinto">Joe Biden&#8217;s Interview With Howard Stern Shows His Intimate Side To Voters: How Hillary Clinton Helped Make The Sit Down Happen</a>
Image: Flickr

Politics

Trump Vs. Biden: 2024 Election Frontrunners Tied In New Poll, Which Candidate Gains In Popularity Among Voters?

Recursion Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NYSE">RXRX</a>) short percent of float has fallen 8.65% since its last report. The company recently reported that it has 39.76 million shares sold short, which is 25.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Recursion Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714681824_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Recursion Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Recursion Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Recursion Pharmaceuticals's peer group average for short interest as a percentage of float is 13.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

RXRX

(RXRX) - Analyzing Recursion Pharmaceuticals's Short Interest

Apple (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.50 by 2 percent. The company reported quarterly sales of $90.800 billion which beat the analystApple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.50 by 2 percent. The company reported quarterly sales of $90.800 billion which beat the analyst consensus estimate of $90.011 billion by 0.88 percent. This is a 4.26 percent decrease over sales of $94.836 billion the same period last year.

Macro Notification

General

Apple Q2 2024 GAAP EPS $1.53 Beats $1.50 Estimate, Sales $90.800B Beat $90.011B Estimate

Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) has outperformed the market over the past 20 years by 3.2% on an annualized basis producing an average annual return of 11.13%. Currently, Regal Rexnord has a market capitalization of $10.81 billion. 
Buying $1000 In RRX: If an investor had bought $1000 of RRX stock 20 years ago, it would be worth $8,378.35 today based on a price of $162.54 for RRX at the time of writing.
<h3>Regal Rexnord's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714681821_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,400 Today

Appili Therapeutics GAAP EPS of -C$0.08

Appili Therapeutics GAAP EPS of -C$0.01

Appili Therapeutics reports Q3 results

Appili Therapeutics Inc Class A (TSE:APLI) has released an update. Appili Therapeutics Inc. has announced a breakthrough in biodefense with the pub...

Appili Therapeutics Advances Tularemia Vaccine

Appili Therapeutics Inc Class A (TSE:APLI) has released an update. Appili Therapeutics Inc., a biopharmaceutical company specializing in infectious...

Appili Therapeutics Acquired by Aditxt for Enhanced Synergies

Aditxt signs agreement to acquire Appili Therapeutics

Appili Therapeutics Secures Bridge Financing

ADTX

Press Releases

Appili Therapeutics Presents at the 10th International Tularemia Conference

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

Health Care

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

Appili Therapeutics Signs Definitive Agreement  to be Acquired by Aditxt, Inc.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Financing

Appili Therapeutics Announces Additional Bridge Loan from  Bloom Burton & Co.

Appili Therapeutics